Full Text:   <1570>

Summary:  <1243>

CLC number: R596.1

On-line Access: 2020-07-07

Received: 2020-01-07

Revision Accepted: 2020-03-22

Crosschecked: 2020-06-05

Cited: 0

Clicked: 2504

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Josef Finsterer

https://orcid.org/0000-0003-2839-7305

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2020 Vol.21 No.7 P.590-592

http://doi.org/10.1631/jzus.B2000010


Secondary manifestations of mitochondrial disorders


Author(s):  Josef Finsterer

Affiliation(s):  Krankenanstalt Rudolfstiftung, Messerli Institute, Vienna, Austria

Corresponding email(s):   fifigs1@yahoo.de

Key Words:  Mitochondrial disorder, nDNA, Multiple mtDNA deletions, Phenotype, Multisystem involvement


Share this article to: More <<< Previous Article|

Josef Finsterer. Secondary manifestations of mitochondrial disorders[J]. Journal of Zhejiang University Science B, 2020, 21(7): 590-592.

@article{title="Secondary manifestations of mitochondrial disorders",
author="Josef Finsterer",
journal="Journal of Zhejiang University Science B",
volume="21",
number="7",
pages="590-592",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000010"
}

%0 Journal Article
%T Secondary manifestations of mitochondrial disorders
%A Josef Finsterer
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 7
%P 590-592
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000010

TY - JOUR
T1 - Secondary manifestations of mitochondrial disorders
A1 - Josef Finsterer
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 7
SP - 590
EP - 592
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000010


Abstract: 
mitochondrial disorders (MIDs) are a heterogeneous group of genetic metabolic diseases due to mutations in the mitochondrial DNA (mtDNA) or in the nuclear DNA (nDNA) (Rahman and Rahman, 2018). Some affected genes encode proteins with various functions, or structural RNAs such as transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs). MIDs may also be caused by mutations in non-coding regions (e.g., D-loop of mtDNA) (Rahman and Rahman, 2018). Proteins involved in MIDs include enzymes, assembling factors, transport proteins, signaling proteins, pore proteins, and fusion/fission proteins (Gorman et al., 2016). The pathways most frequently affected by mutations in “mitochondrial genes” are the respiratory chain and the oxidative phosphorylation. Dysfunction of many other pathways (e.g., β-oxidation, pyruvate-dehydrogenase complex, and heme synthesis) may also manifest as MIDs (Hu et al., 2019). The estimated prevalence of MIDs is at least 1:5000 (Ng and Turnbull, 2016).

线粒体病的继发表现

概要:线粒体病(MID)是由线粒体DNA(mtDNA)或核DNA(nDNA)基因突变引起的一组异质性遗传代谢疾病.由于其广泛的遗传异质性,MID具有多种表型.有时,受MID影响的器官可能会因另一器官、组织、系统的继发性疾病而变得复杂.继发性并发症可通过动脉、神经或内分泌信号从原发部位传播.动脉受MID影响可能会导致动脉高压、缺血、出血或动脉瘤形成.癫痫发作可能与创伤性脑损伤、Takotsubo综合征或癫痫猝死(SUDEP)有关.垂体腺瘤可能引起皮质功能减退、动脉低血压、性腺功能减退或身材矮小.糖尿病或甲状旁腺功能减退可能与神经病变、动脉低血压、低钙血症或视野缺损有关.肾脏受累可引起动脉高压.肝脏或免疫细胞受累可能会导致感染.MID的继发性表现可能会严重影响治疗管理、疾病轨迹和患者预后,因此需要仔细评估.
关键词:线粒体疾病(MID);核DNA(nDNA);多重由线粒体DNA缺失;表型;多系统参与

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Emma F, Salviati L, 2017. Mitochondrial cytopathies and the kidney. Néphrol Thér, 13(S1):S23-S28.

[2]Finsterer J, 2012. Inherited mitochondrial disorders. In: Scatena R, Bottoni P, Giardina B (Eds.), Advances in Mitochondrial Medicine. Springer, Dordrecht, p.187-213.

[3]Finsterer J, 2018. Clinical perspectives of mitochondrial disorders. Pediatr Endocrinol Rev, 16(1):203-208.

[4]Finsterer J, Zarrouk-Mahjoub S, 2016. Mitochondrial vasculopathy. World J Cardiol, 8(5):333-339.

[5]Finsterer J, Melichart-Kotig M, Woehrer A, 2019. Mitochondrial disorder mimicking rheumatoid disease. Z Rheumatol, 78(9):875-880.

[6]Galassi G, Maggi L, Lamantea E, et al., 2017. C10ORF2 mutation associated with progressive external ophthalmoplegia and clinically isolated syndrome. Acta Neurol Belg, 117(4):947-949.

[7]Gorman GS, Chinnery PF, DiMauro S, et al., 2016. Mitochondrial diseases. Nat Rev Dis Primers, 2(1):16080.

[8]Hu SY, Zhuang QQ, Qiu Y, et al., 2019. Cell models and drug discovery for mitochondrial diseases. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(5):449-456.

[9]Kalashnikova LA, Sakharova AV, Dobrynina LA, et al., 2010. Mitochondrial arteriopathy as a cause of spontaneous dissection of cerebral arteries. Zh Nevrol Psikhiatr Im S S Korsakova, 110(4 Suppl 2):3-11 (in Russian).

[10]Kennedy H, Haack TB, Hartill V, et al., 2016. Sudden cardiac death due to deficiency of the mitochondrial inorganic pyrophosphatase PPA2. Am J Hum Genet, 99(3):674-682.

[11]Kytövuori L, Lipponen J, Rusanen H, et al., 2016. A novel mutation m.8561C>G in MT-ATP6/8 causing a mitochondrial syndrome with ataxia, peripheral neuropathy, diabetes mellitus, and hypergonadotropic hypogonadism. J Neurol, 263(11):2188-2195.

[12]Lin L, Cui P, Qiu ZP, et al., 2019. The mitochondrial tRNAAla 5587T>C and tRNALeu(CUN) 12280A>G mutations may be associated with hypertension in a Chinese family. Exp Ther Med, 17(3):1855-1862.

[13]Malfatti E, Laforêt P, Jardel C, et al., 2013. High risk of severe cardiac adverse events in patients with mitochondrial m.3243A>G mutation. Neurology, 80(1):100-105.

[14]Mima A, Shiota F, Matsubara T, et al., 2011. An autopsy case of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with intestinal bleeding in chronic renal failure. Ren Fail, 33(6):622-625.

[15]Nandal S, Castles A, Asrar ul Haq M, et al., 2019. Takotsubo cardiomyopathy triggered by status epilepticus: case report and literature review. BMJ Case Rep, 12(1):e225924.

[16]Ng YS, Turnbull DM, 2016. Mitochondrial disease: genetics and management. J Neurol, 263:179-191.

[17]Rahman J, Rahman S, 2018. Mitochondrial medicine in the omics era. Lancet, 391(10139):2560-2574.

[18]Rahman S, 2019. Advances in the treatment of mitochondrial epilepsies. Epilepsy Behav, 101:106546.

[19]Rahman S, 2020. Mitochondrial disease in children. J Intern Med, 287:609-633.

[20]Sun XR, Jiang GH, Ju XY, et al., 2018. MELAS and macroangiopathy: a case report and literature review. Medicine, 97(52):e13866.

[21]Tay SHK, Nordli DR Jr, Bonilla E, et al., 2006. Aortic rupture in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. Arch Neurol, 63(2):281-283.

[22]Varanasi SS, Francis RM, Berger CEM, et al., 1999. Mitochondrial DNA deletion associated oxidative stress and severe male osteoporosis. Osteoporos Int, 10(2):143-149.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE